These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2569956)

  • 1. [Treatment of progressive supranuclear palsy].
    Finali G; Piccinin GL; Piccirilli M; Stefano E
    Clin Ter; 1989 Jun; 129(5):339-51. PubMed ID: 2569956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Descriptive study of a serie of patients affected by progressive supranuclear palsy].
    Villanueva-Haba VE; Garcés M; de Vera A; Valero C; Burguera JA
    Rev Neurol; 2001 Jun 1-15; 32(11):1027-30. PubMed ID: 11562823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.
    Yarnall AJ; Burn DJ
    Age Ageing; 2012 Sep; 41(5):695-6. PubMed ID: 22421702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward future therapies in progressive supranuclear palsy.
    Burn DJ; Warren NM
    Mov Disord; 2005 Aug; 20 Suppl 12():S92-8. PubMed ID: 16092097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of progressive supranuclear palsy and corticobasal degeneration.
    Lang AE
    Mov Disord; 2005 Aug; 20 Suppl 12():S83-91. PubMed ID: 16092096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Treatment Options for Progressive Supranuclear Palsy.
    Stamelou M; Höglinger G
    CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy.
    O'Sullivan SS; Djamshidian A; Ahmed Z; Evans AH; Lawrence AD; Holton JL; Revesz T; Lees AJ
    Mov Disord; 2010 Apr; 25(5):638-42. PubMed ID: 20213825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Steele-Richardson-Olszewski syndrome].
    Mano Y
    Nihon Rinsho; 1993 Nov; 51(11):2962-7. PubMed ID: 7903988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank.
    Josephs KA; Dickson DW
    Mov Disord; 2003 Sep; 18(9):1018-26. PubMed ID: 14502669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autonomic dysfunction in patients with progressive supranuclear palsy.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Reichmann H; Berg D; Ziemssen T
    Mov Disord; 2008 Oct; 23(14):2083-9. PubMed ID: 18792126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.
    Birdi S; Rajput AH; Fenton M; Donat JR; Rozdilsky B; Robinson C; Macaulay R; George D
    Mov Disord; 2002 Nov; 17(6):1255-64. PubMed ID: 12465065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
    Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
    Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy.
    Bergmann KJ; Salak VL
    Parkinsonism Relat Disord; 2008; 14(4):348-52. PubMed ID: 17825599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excessive dopamine neuron loss in progressive supranuclear palsy.
    Murphy KE; Karaconji T; Hardman CD; Halliday GM
    Mov Disord; 2008 Mar; 23(4):607-10. PubMed ID: 18163454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
    Villares J; Faucheux B; Herrero MT; Obeso JA; Duyckaerts C; Hauw JJ; Agid Y; Hirsch EC
    Exp Neurol; 1998 Nov; 154(1):146-56. PubMed ID: 9875276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T
    Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive supranuclear palsy: analysis of six cases.
    Marra M; Toni V; Trianni G; Coppola G
    Neurol Sci; 2003 Oct; 24(3):186-7. PubMed ID: 14598079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Ashour R; Jankovic J
    Mov Disord; 2006 Nov; 21(11):1856-63. PubMed ID: 16941460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of progressive supranuclear palsy showing improvement of rigidity, nuchal dystonia and autonomic failure with trazodone].
    Kato E; Takahashi S; Abe T; Kawamorita A; Tohgi H
    Rinsho Shinkeigaku; 1994 Oct; 34(10):1013-7. PubMed ID: 7834944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.